Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Aarkstore Enterprise Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry

Posted Jan 21 2011 4:22am
Aarkstore announce a new report  "Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market" through its vast collection of market research report.

Summary

A leading business intelligence provider, has released its latest research, “Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market”. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global antihypertensive market. The report analyzes the markets for antihypertensive disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes:
- Annualized market data for the antihypertensive disorders market from 2002 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including hypertension and PAH.
- Analysis of the antihypertensive disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the antihypertensive disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Novartis, Merck, AstraZeneca, United Therapeutics, Actelion and Pfizer.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global antihypertensive disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

For more information, please visit:
http://www.aarkstore.com/reports/Antihypertensives-Market-to-2016-Generic-Erosio
Or email us at press@aarkstore.com or call +919272852585
Post a comment
Write a comment: